NASDAQ:TSHA Taysha Gene Therapies (TSHA) Stock Price, News & Analysis $2.04 -0.07 (-3.32%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.99▼$2.1350-Day Range$2.02▼$2.4652-Week Range$1.27▼$4.32Volume2.88 million shsAverage Volume996,494 shsMarket Capitalization$418.08 millionP/E RatioN/ADividend YieldN/APrice Target$6.22 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Taysha Gene Therapies alerts: Email Address Taysha Gene Therapies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside205.0% Upside$6.22 Price TargetShort InterestHealthy10.14% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingAcquiring Shares$3 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.35) to ($0.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.67 out of 5 starsMedical Sector401st out of 910 stocksBiological Products, Except Diagnostic Industry56th out of 155 stocks 4.5 Analyst's Opinion Consensus RatingTaysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTaysha Gene Therapies has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Taysha Gene Therapies' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.14% of the outstanding shares of Taysha Gene Therapies have been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Taysha Gene Therapies has recently decreased by 10.47%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTaysha Gene Therapies does not currently pay a dividend.Dividend GrowthTaysha Gene Therapies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TSHA. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Taysha Gene Therapies this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for TSHA on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -82% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Taysha Gene Therapies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,999,999.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of Taysha Gene Therapies is held by insiders.Percentage Held by Institutions77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Taysha Gene Therapies' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Taysha Gene Therapies are expected to decrease in the coming year, from ($0.35) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Taysha Gene Therapies is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Taysha Gene Therapies is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTaysha Gene Therapies has a P/B Ratio of 3.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Taysha Gene Therapies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About Taysha Gene Therapies Stock (NASDAQ:TSHA)Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.Read More TSHA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TSHA Stock News HeadlinesSeptember 6 at 8:00 AM | globenewswire.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 5 at 8:13 AM | 247wallst.com3 Penny Stocks to Buy With $100September 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 28, 2024 | americanbankingnews.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Rating of "Buy" by AnalystsAugust 28, 2024 | americanbankingnews.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.22 Average Target Price from AnalystsAugust 18, 2024 | finance.yahoo.comTaysha Gene Therapies Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagAugust 16, 2024 | finance.yahoo.comTSHA Sep 2024 1.000 put (TSHA240920P00001000)August 14, 2024 | markets.businessinsider.comBuy Rating for Taysha Gene Therapies Backed by Extended Cash Runway and Promising Trial ProspectsSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 14, 2024 | markets.businessinsider.comMaintained Buy Rating on Taysha Gene Therapies Amid Progress and Solid FinancialsAugust 14, 2024 | finanznachrichten.deTaysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Taysha Gene Therapies Amid Strong Financials and Promising Clinical TrialsAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Taysha Gene Therapies Amid Strategic Planning and Potential Drug EfficacyAugust 12, 2024 | seekingalpha.comTaysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | investorplace.comTSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Misses Revenue for Q2 2024August 12, 2024 | globenewswire.comTaysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 5, 2024 | finance.yahoo.comTaysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12August 2, 2024 | globenewswire.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive TSHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TSHA CUSIPN/A CIK1806310 Webwww.tayshagtx.com Phone214-612-0000FaxN/AEmployees180Year Founded2020Price Target and Rating Average Stock Price Target$6.22 High Stock Price Target$8.00 Low Stock Price Target$5.00 Potential Upside/Downside+205.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-111,570,000.00 Net Margins-888.18% Pretax Margin-888.18% Return on Equity-168.91% Return on Assets-44.12% Debt Debt-to-Equity Ratio0.35 Current Ratio5.22 Quick Ratio5.22 Sales & Book Value Annual Sales$15.45 million Price / Sales27.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.53 per share Price / Book3.85Miscellaneous Outstanding Shares204,940,000Free Float181,969,000Market Cap$418.08 million OptionableOptionable Beta0.41 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Sean P. Nolan (Age 56)CEO & Chairman Comp: $925.33kDr. Sukumar Nagendran M.D. (Age 57)President, Head of Research & Development and Director Comp: $820.59kMr. Kamran Alam CPA (Age 46)M.B.A., CFO & Corporate Secretary Comp: $573.36kHayleigh CollinsDirector of Corporate Communications & Investor RelationsMs. Tracy M. Porter SPHRChief People OfficerMr. Frederick Porter Ph.D.Chief of Staff & Technical Operations OfficerMs. Emily McGinnis M.P.H.Chief Patient Advocacy & External Affairs OfficerMr. Sean McAuliffeChief Business OfficerDr. Steven Gray Ph.D.Chief Scientific Advisor of UT Southwestern Gene Therapy ProgramBerge Minassian M.D.Chief Medical Advisor of UT Southwestern Gene Therapy ProgramMore ExecutivesKey CompetitorsNantKwestNASDAQ:NKVaxartNASDAQ:VXRTTCR2 TherapeuticsNASDAQ:TCRRPassage BioNASDAQ:PASGEdgewise TherapeuticsNASDAQ:EWTXView All CompetitorsInsiders & InstitutionsThe Manufacturers Life Insurance Company Bought 69,487 shares on 8/15/2024Ownership: 0.071%Scientech Research LLCBought 43,350 shares on 8/15/2024Ownership: 0.023%Marshall Wace LLPSold 244,563 shares on 8/14/2024Ownership: 0.420%Squarepoint Ops LLCSold 133,691 shares on 8/14/2024Ownership: 0.043%Marathon Trading Investment Management LLCSold 178,560 shares on 8/12/2024Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions TSHA Stock Analysis - Frequently Asked Questions How have TSHA shares performed this year? Taysha Gene Therapies' stock was trading at $1.77 at the start of the year. Since then, TSHA stock has increased by 15.3% and is now trading at $2.04. View the best growth stocks for 2024 here. How were Taysha Gene Therapies' earnings last quarter? Taysha Gene Therapies, Inc. (NASDAQ:TSHA) issued its quarterly earnings results on Monday, August, 12th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. The company earned $1.11 million during the quarter, compared to analysts' expectations of $3.62 million. Taysha Gene Therapies had a negative trailing twelve-month return on equity of 168.91% and a negative net margin of 888.18%. When did Taysha Gene Therapies IPO? Taysha Gene Therapies (TSHA) raised $125 million in an IPO on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager. Who are Taysha Gene Therapies' major shareholders? Top institutional investors of Taysha Gene Therapies include Marshall Wace LLP (0.42%), Quantum Private Wealth LLC (0.39%), Bank of New York Mellon Corp (0.24%) and Rhumbline Advisers (0.10%). Insiders that own company stock include RA Session II, Sean P Nolan, Paul B Manning, Suyash Prasad, Kamran Alam, Sukumar Nagendran and Phillip B Donenberg. View institutional ownership trends. How do I buy shares of Taysha Gene Therapies? Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TSHA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Taysha Gene Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
